Skip to main content

Table 2 Pooled results of the meta-analysis of the diagnostic accuracy of CTCs detection in gastric cancer

From: Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis

Analysis scenario Sensitivity Specificity Positive LR Negative LR DOR Heterogeneity*
All studies 0.42 (0.21, 0.67) 0.99 (0.96, 1.00) 58.2 ( 9.8, 345.9) 0.58 (0.38, 0.89) 100 (15, 663) 98 (98, 99)
All studies without outliers 0.37 (0.16, 0.65) 0.99 (0.96, 1.00) 65.4 (8.4, 511.4) 0.63 (0.42, 0.96) 104 (11, 956) 94 (89, 99)
Subgroup: CEA 0.31 (0.10, 0.64) 0.94 (0.87, 0.98) 5.4 (2.1, 14.0) 0.73 (0.49, 1.09) 7 ( 2, 26) 98 (96, 99)
Subgroup: CK-19 0.27 (0.06, 0.67) 0.95 (0.90, 0.98) 5.4 (1.7, 16.4) 0.77 (0.50, 1.19) 7 (2, 31) 97 (96, 99)
Subgroup: CK-20 0.25 (0.13, 0.43) 0.95 (0.89, 0.98) 4.9 (1.6, 14.9) 0.79 (0.64, 0.98) 6 (2, 23) 0 (0, 100)
Subgroup: stage 1 0.22 (0.06, 0.56) 0.95 (0.89, 0.98) 4.3 (1.1, 17.7) 0.82 (0.59, 1.15) 5 (1, 29) 91 (83, 100)
Subgroup: stage 2 0.40 (0.14, 0.73) 0.96 (0.90, 0.98) 9.7 (4.5, 20.9) 0.62 (0.37, 1.07) 15 (5, 48) 93 (86, 99)
Subgroup: stage 3 0.46 (0.16, 0.80) 0.95 (0.90, 0.98) 9.4 (3.4, 25.9) 0.56 (0.28, 1.15) 17 (3, 83) 94 (89, 99)
Subgroup: stage 4 0.63 (0.43, 0.79) 0.97 (0.95, 0.98) 20.6 (11.2, 38.0) 0.38 (0.23, 0.64) 54 (21, 138) 71 (35,100)
Subgroup: stage 1-3 0.30 (0.09, 0.64) 0.96 (0.91, 0.98) 6.9 (2.2,21.3) 0.73 (0.48, 1.12) 9 (2, 42) 97 (95, 99)
Subgroup: PCR-based assay 0.39 (0.20, 0.60) 0.94 (0.90, 0.96) 6.1 (3.6, 10.4) 0.94 (0.90, 0.96) 9 (4, 21) 96 (95, 97)
Subgroup: immunological assay 0.82 (0.43, 1.00) 1.00 (0.98, 1.00) 74.5 (15.0,368.9) 0.335 (0.12-0.97) 340.9 (23.26,4996.7) 93 (88, 97)
  1. Numbers in parentheses are 95% CIs. DOR diagnostic odds ratio, LR likelihood ratio.
  2. * Inconsistency indexes are percentages.